Top Page
Recce Pharmaceuticals Ltd.
(Sydney:RCE)
Recce Pharmaceuticals Ltd. (RCE) vs. iShares MSCI Australia ETF (EWA)
Recce Pharmaceuticals Ltd. Business Overview & Revenue Model
Recce Pharmaceuticals Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.51M | 7.51M | 5.03M | 4.37M | 3.08M | 1.64M |
| Gross Profit | -2.94M | -2.94M | -2.19M | 4.15M | 2.90M | 1.34M |
| EBITDA | -20.28M | -20.33M | -21.35M | -16.99M | -13.87M | -14.77M |
| Net Income | -21.43M | -21.43M | -17.66M | -13.08M | -10.99M | -13.51M |
Balance Sheet | ||||||
| Total Assets | 12.41M | 12.41M | 6.37M | 2.56M | 12.62M | 21.68M |
| Cash, Cash Equivalents and Short-Term Investments | 10.45M | 10.45M | 4.42M | 1.56M | 11.58M | 20.87M |
| Total Debt | 10.77M | 10.77M | 811.19K | 250.57K | 74.76K | 126.95K |
| Total Liabilities | 15.47M | 15.47M | 15.89M | 5.14M | 2.56M | 1.18M |
| Stockholders Equity | -3.05M | -3.05M | -9.52M | -2.59M | 10.06M | 20.50M |
Cash Flow | ||||||
| Free Cash Flow | -20.47M | -20.47M | -13.15M | -12.73M | -9.05M | -7.93M |
| Operating Cash Flow | -20.44M | -20.44M | -13.01M | -12.69M | -9.01M | -7.86M |
| Investing Cash Flow | -443.90K | -443.90K | -141.90K | -38.63K | -40.34K | -76.01K |
| Financing Cash Flow | 26.92M | 26.92M | 16.00M | 2.71M | -240.50K | 26.12M |
Recce Pharmaceuticals Ltd. Technical Analysis
Recce Pharmaceuticals Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$87.22M | -8.46 | -27.39% | ― | ― | 26.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$87.28M | -9.12 | -49.72% | ― | ― | 10.78% | |
47 Neutral | AU$123.67M | -1.23 | -83.09% | ― | ― | 55.94% | |
44 Neutral | AU$193.03M | -7.40 | ― | ― | ― | 0.66% | |
44 Neutral | AU$111.71M | -13.68 | -47.98% | ― | 700.00% | 26.88% | |
41 Neutral | AU$97.88M | -5.26 | -42.68% | ― | ― | 63.46% |
Recce Pharmaceuticals Ltd. Corporate Events
Recce Pharmaceuticals has been awarded an Advanced Overseas Finding for up to A$85 million by the Australian Government, which extends the 43.5% R&D Tax Incentive to the company’s overseas R&D activities for three years. This decision supports Recce’s global anti-infective programs, including a Phase 3 clinical trial for Diabetic Foot Infection in Indonesia, and highlights the company’s efforts in addressing antibiotic resistance.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.52 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
Recce Pharmaceuticals Ltd. announced the granting of a patent in Hong Kong for its anti-infective products, RECCE® 327 and RECCE® 529, which are used to treat various infections. This patent strengthens Recce’s intellectual property portfolio in Asia, supporting its strategy to enter markets with significant medical and commercial potential, such as the ASEAN region, where it is also progressing with a Phase 3 clinical trial in Indonesia.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
Recce Pharmaceuticals Ltd. announced positive preclinical results for its synthetic anti-infective, RECCE® 327, in treating hospital-acquired pneumonia caused by multidrug-resistant Acinetobacter baumannii in mice models. The study demonstrated that nebulised R327 significantly reduced bacterial load in the lungs, outperforming traditional antibiotics like meropenem, which face solubility challenges. This advancement highlights R327’s potential as a critical treatment option in hospital settings, particularly for drug-resistant lung infections, and underscores its versatility and efficacy in direct lung delivery.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
Recce Pharmaceuticals Ltd. announced the passing of its founder, Dr. Graham JH Melrose, a pioneer in polymer chemistry and infectious diseases. His leadership and vision were instrumental in establishing Recce as a notable player in the biotech industry, focusing on innovative solutions to antibiotic resistance. Dr. Melrose’s legacy continues to inspire the company’s mission and future innovations.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
Recce Pharmaceuticals Ltd held its 2025 Annual General Meeting, where all resolutions were decided by poll. Notably, the re-election of Dr. John Prendergast and Dr. Justin Ward as directors was carried, while resolutions related to the future issue of securities and ratification of prior share and warrant issues were not carried. The outcome of the meeting, including a ‘first strike’ against the remuneration report, may impact the company’s governance and future strategic decisions.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
Recce Pharmaceuticals Ltd presented at their Annual General Meeting in 2025, highlighting their strategic intentions and future plans. The presentation emphasized the company’s commitment to innovation in the pharmaceutical sector, particularly in combating antibiotic resistance. While the document outlines potential future strategies, it also acknowledges the inherent risks and uncertainties that could impact the company’s performance and operations.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
Recce Pharmaceuticals Ltd has commenced patient dosing in a Phase 3 clinical trial for diabetic foot infections in Indonesia, aiming to enroll up to 310 patients. This trial is significant due to Indonesia’s high diabetes prevalence and the urgent need for new treatment solutions. The company’s RECCE® 327 Topical Gel has shown high efficacy against antibiotic-resistant pathogens, highlighting its potential impact on the treatment of chronic wounds and positioning Recce as a key player in addressing global health challenges.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
Recce Pharmaceuticals Ltd announced a change in the director’s interest, specifically concerning James Graham, who has disposed of 745,962 Class B Performance Shares through a selective buy-back approved by shareholders. This change reflects a strategic adjustment in the company’s equity structure, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
Recce Pharmaceuticals Ltd has announced the cessation of 8,754,423 performance shares due to a selective buy-back, effective October 7, 2025. This move may impact the company’s capital structure and could be part of a strategic effort to optimize shareholder value and streamline operations, signaling potential shifts in their market positioning.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
Recce Pharmaceuticals Ltd has announced the final notification of its selective buy-back of performance shares, totaling 8,754,423 securities at a consideration of AUD 87.54. This strategic move is likely to impact the company’s financial structure and could influence its market positioning by potentially increasing shareholder value.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
Recce Pharmaceuticals Ltd has announced an update regarding its selective buy-back of performance shares, identified by the ASX security code RCEAH. The update pertains to the date of the buy-back occurring, which has been changed from the initially notified date. This announcement could impact stakeholders by altering the timeline of the buy-back process, potentially affecting the company’s share structure and market perception.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
Recce Pharmaceuticals Ltd announced the dispatch of documents related to its 2025 Annual General Meeting to shareholders. The company’s innovative anti-infective solutions, which have garnered significant recognition, position it as a key player in addressing global health challenges related to antibiotic resistance. The upcoming meeting is set to discuss these advancements and their implications for stakeholders.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.